These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 2297713)
1. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. DeNardo GL; DeNardo SJ; O'Grady LF; Levy NB; Adams GP; Mills SL Cancer Res; 1990 Feb; 50(3 Suppl):1014s-1016s. PubMed ID: 2297713 [TBL] [Abstract][Full Text] [Related]
2. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. DeNardo SJ; DeNardo GL; O'Grady LF; Hu E; Sytsma VM; Mills SL; Levy NB; Macey DJ; Miller CH; Epstein AL Int J Cancer Suppl; 1988; 3():96-101. PubMed ID: 3209308 [TBL] [Abstract][Full Text] [Related]
3. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684 [TBL] [Abstract][Full Text] [Related]
4. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379 [TBL] [Abstract][Full Text] [Related]
5. Milestones in the development of Lym-1 therapy. DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782 [TBL] [Abstract][Full Text] [Related]
6. 131I-Lym-1 in mice implanted with human Burkitt's lymphoma (Raji) tumors: loss of tumor specificity due to radiolysis. DeNardo GL; DeNardo SJ; Wessels BW; Kukis DL; Miyao N; Yuan A Cancer Biother Radiopharm; 2000 Dec; 15(6):547-60. PubMed ID: 11190487 [TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377 [TBL] [Abstract][Full Text] [Related]
8. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Knox SJ; Levy R; Miller RA; Uhland W; Schiele J; Ruehl W; Finston R; Day-Lollini P; Goris ML Cancer Res; 1990 Aug; 50(16):4935-40. PubMed ID: 2379158 [TBL] [Abstract][Full Text] [Related]
9. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma. DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704 [TBL] [Abstract][Full Text] [Related]
10. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752 [TBL] [Abstract][Full Text] [Related]
11. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji). DeNardo GL; Kukis DL; Shen S; Mausner LF; Meares CF; Srivastava SC; Miers LA; DeNardo SJ Clin Cancer Res; 1997 Jan; 3(1):71-9. PubMed ID: 9815540 [TBL] [Abstract][Full Text] [Related]
13. Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model. Kroger LA; DeNardo SJ; DeNardo GL; Xiong CY; Winthrop MD; Gumerlock PH Clin Cancer Res; 1999 Oct; 5(10 Suppl):3010s-3014s. PubMed ID: 10541336 [TBL] [Abstract][Full Text] [Related]
14. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. DeNardo SJ; Kroger LA; MacKenzie MR; Mirick GR; Shen S; DeNardo GL Cancer Biother Radiopharm; 1998 Feb; 13(1):1-12. PubMed ID: 10850337 [TBL] [Abstract][Full Text] [Related]
15. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368 [TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors. Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902 [TBL] [Abstract][Full Text] [Related]
17. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378 [TBL] [Abstract][Full Text] [Related]
19. Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1.1 monoclonal antibody. Badger CC; Krohn KA; Peterson AV; Shulman H; Bernstein ID Cancer Res; 1985 Apr; 45(4):1536-44. PubMed ID: 3978621 [TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Richman CM; DeNardo SJ; O'Grady LF; DeNardo GL Cancer Res; 1995 Dec; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]